C1q potentiates DR5 agonist activity by a mixture of two DR5-specific HexaBody molecules

Author(s):
Beurskens, F.; Overdijk, M.; Strumane, K.; Buijssel, A.O.; Vermot-Desroches, C.; Kroes, T.; Jong, B. de; Hoevenaars, N.; Jong, R. de; Lingnau, A.; Parren, P.; Schuurman, J.; Breij, E.
Published
2018
Publication type
Other
C1qImmunotherapyCrosslinkingCancerDR5Hexamerization
Date issued
2018-10-01
Language
English
Publisher
PERGAMON-ELSEVIER SCIENCE LTD
hdl
1887/121518
doi
10.1016/j.molimm.2018.06.031